Previous Close | $0.27 |
Intrinsic Value | $0.84 |
Upside potential | +209% |
Data is not available at this time.
Biodesix, Inc. operates in the diagnostics and data-driven solutions sector, specializing in advanced blood-based testing for lung diseases, including lung cancer and COVID-19. The company leverages proprietary artificial intelligence and machine learning to deliver actionable insights, supporting personalized treatment decisions for clinicians. Its revenue model is primarily driven by diagnostic test sales, biopharmaceutical partnerships, and data services, positioning it as a niche player in precision medicine. Biodesix competes in a rapidly evolving market, where demand for non-invasive diagnostic tools is growing, particularly in oncology and infectious disease management. The company’s focus on innovative, clinically validated tests differentiates it from traditional lab service providers, though it faces competition from larger diagnostic firms and emerging biotech entrants. Its market position is bolstered by strategic collaborations with healthcare providers and biopharma companies, enhancing its commercial reach and technological credibility.
Biodesix reported revenue of $71.3 million for the fiscal year ending December 31, 2024, reflecting its diagnostic test sales and partnership-driven income streams. However, the company posted a net loss of $42.9 million, with diluted EPS of -$0.33, indicating ongoing challenges in achieving profitability. Operating cash flow was negative at $48.6 million, while capital expenditures totaled $3.2 million, underscoring significant cash burn as it invests in growth and R&D.
The company’s negative earnings and cash flow highlight its current reliance on external funding to sustain operations. With a capital-intensive business model focused on diagnostic innovation, Biodesix’s capital efficiency remains under pressure. Its ability to scale test volumes and secure recurring revenue from biopharma collaborations will be critical to improving earnings power over time.
Biodesix’s balance sheet shows $26.2 million in cash and equivalents against $62.0 million in total debt, raising liquidity concerns given its negative cash flow. The high debt burden relative to cash reserves suggests potential refinancing risks, though the company may rely on equity raises or strategic partnerships to bridge funding gaps. Financial health remains fragile, requiring careful capital management.
Revenue growth is driven by expanding test adoption and biopharma contracts, but profitability remains elusive. The company does not pay dividends, reinvesting all cash flows into growth initiatives. Future trends hinge on commercial execution, regulatory approvals for new tests, and scalability of its AI-driven platform in competitive diagnostic markets.
Market expectations for Biodesix are tempered by its unprofitability and cash burn, though its niche in precision diagnostics offers long-term potential. Valuation likely reflects speculative growth prospects rather than near-term earnings, with investors betting on its ability to capture market share in liquid biopsy and data-driven healthcare solutions.
Biodesix’s proprietary technology and focus on lung disease diagnostics provide a differentiated edge, but execution risks persist. The outlook depends on achieving scale, securing additional partnerships, and navigating a capital-intensive growth phase. Success in these areas could position the company as a leader in AI-enhanced diagnostics, though near-term challenges remain significant.
Company filings, CIK 0001439725
show cash flow forecast
Fiscal year | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | 2034 | 2035 | 2036 | 2037 | 2038 | 2039 | 2040 | 2041 | 2042 | 2043 | 2044 | 2045 | 2046 | 2047 | 2048 | 2049 | |
INCOME STATEMENT | ||||||||||||||||||||||||||
Revenue growth rate, % | NaN | |||||||||||||||||||||||||
Revenue, $ | NaN | |||||||||||||||||||||||||
Variable operating expenses, $m | NaN | |||||||||||||||||||||||||
Fixed operating expenses, $m | NaN | |||||||||||||||||||||||||
Total operating expenses, $m | NaN | |||||||||||||||||||||||||
Operating income, $m | NaN | |||||||||||||||||||||||||
EBITDA, $m | NaN | |||||||||||||||||||||||||
Interest expense (income), $m | NaN | |||||||||||||||||||||||||
Earnings before tax, $m | NaN | |||||||||||||||||||||||||
Tax expense, $m | NaN | |||||||||||||||||||||||||
Net income, $m | NaN | |||||||||||||||||||||||||
BALANCE SHEET | ||||||||||||||||||||||||||
Cash and short-term investments, $m | NaN | |||||||||||||||||||||||||
Total assets, $m | NaN | |||||||||||||||||||||||||
Adjusted assets (=assets-cash), $m | NaN | |||||||||||||||||||||||||
Average production assets, $m | NaN | |||||||||||||||||||||||||
Working capital, $m | NaN | |||||||||||||||||||||||||
Total debt, $m | NaN | |||||||||||||||||||||||||
Total liabilities, $m | NaN | |||||||||||||||||||||||||
Total equity, $m | NaN | |||||||||||||||||||||||||
Debt-to-equity ratio | NaN | |||||||||||||||||||||||||
Adjusted equity ratio | NaN | |||||||||||||||||||||||||
CASH FLOW | ||||||||||||||||||||||||||
Net income, $m | NaN | |||||||||||||||||||||||||
Depreciation, amort., depletion, $m | NaN | |||||||||||||||||||||||||
Funds from operations, $m | NaN | |||||||||||||||||||||||||
Change in working capital, $m | NaN | |||||||||||||||||||||||||
Cash from operations, $m | NaN | |||||||||||||||||||||||||
Maintenance CAPEX, $m | NaN | |||||||||||||||||||||||||
New CAPEX, $m | NaN | |||||||||||||||||||||||||
Total CAPEX, $m | NaN | |||||||||||||||||||||||||
Free cash flow, $m | NaN | |||||||||||||||||||||||||
Issuance/(repurchase) of shares, $m | NaN | |||||||||||||||||||||||||
Retained Cash Flow, $m | NaN | |||||||||||||||||||||||||
Pot'l extraordinary dividend, $m | NaN | |||||||||||||||||||||||||
Cash available for distribution, $m | NaN | |||||||||||||||||||||||||
Discount rate, % | NaN | |||||||||||||||||||||||||
PV of cash for distribution, $m | NaN | |||||||||||||||||||||||||
Current shareholders' claim on cash, % | NaN |